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Abstract
 .  .Glycosylphosphatidylinositol-specific phospholipase D GPI-PLD EC 3.1.4.50 from mammalian serum is a 115 kDa
glycoprotein consisting of 816 amino acids. We found that C-terminal deletions of only two to five amino acids reduced
GPI-PLD enzymatic activity by roughly 70% as compared to wild-type protein. C-terminal deletions of more than five
amino acids resulted in a complete loss of GPI-PLD enzymatic activity. Point mutations at position 811 indicate that
Tyr-811 may play a major role in maintaining the biological activity of GPI-PLD.
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1. Introduction
Glycosylphosphatidylinositol-specific phospholi-
 .apase D GPI-PLD is a 115 kDa glycoprotein pre-
w xsent in large amounts in mammalian serum 1–4 . As
w xdeduced from its cDNA 5 , the mature protein
stretches over 816 amino acids. GPI-PLD hydrolyzes
 .glycosylphosphatidylinositol GPI structures which
are used by a large number of cell surface proteins as
membrane anchors. Therefore, GPI-PLD has been
postulated to be involved in the selective release of
GPI-anchored proteins from cell surfaces into the
w xextracellular space 6 . However, in vitro studies have
Abbreviations: GPI-PLD, glycosylphosphatidylinositol-
specific phospholipase D; PBS, phosphate-buffered saline; FCS,
fetal calf serum; SDS, sodium dodecyl sulfate; PAGE, polyacryl-
amide gel electrophoresis; PI, phosphatidylinositol
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shown that GPI-PLD hydrolyzes only detergent-
solubilized GPI-anchored proteins and is virtually
w xinactive on membrane-bound GPI substrates 2,7 .
GPI-PLD has also been demonstrated in mammalian
w xtissue cells 8–12 and it has been postulated that an
intracellular compartment may provide a more
favourable environment for GPI-PLD action. Studies
in which GPI-anchored proteins and GPI-PLD have
been cotransfected into COS-1 cells support this hy-
w x w xpothesis 5,13 . In addition, Metz et al. 14 have
recently shown that a cell-associated GPI-PLD was
able to release GPI-anchored proteins in vivo.
It has been reported that small amounts of GPI-PLD
in mammalian serum may exist as an active 47 kDa
w xform 15 . Furthermore, trypsin was shown to cleave
the intact form of GPI-PLD into three distinct pep-
tides. GPI-PLD activity was associated with a N-
terminal fragment of apparent molecular mass of 38.6
kDa that also retained the specificity for GPI sub-
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 w x.strates i.e. PI was not hydrolyzed; 16,17 . Recently,
we transfected COS-1 cells with a corresponding
N-terminal 1.06 kb fragment of GPI-PLD cDNA and
found that the expected N-terminal protein fragment
was expressed. However, in contrast to the GPI-PLD
fragment generated by trypsin treatment, the N-termi-
nal fragment expressed in COS-1 cells showed no
GPI anchor-hydrolyzing activity Kung, M. and¨
.Stadelmann, B., unpublished data . This observation
suggested that the C-terminus of the protein may
have a role in maintaining structural integrity of
GPI-PLD. In this report we investigated the influence
of the C-terminus of GPI-PLD on its enzymatic
activity by expression of C-terminal deletion and
substitution mutants in COS-1 cells.
2. Materials and methods
2.1. Reagents and materials
All reagents were of analytical grade and either
 .from Boehringer Mannheim, Germany , Fluka
 .  .Buchs, Switzerland , Sigma St. Louis, MO, USA
 .or Merck Darmstadt, Germany . Dulbecco’s modi-
 .fied Eagle’s medium DMEM with L-glutamine was
 .from Seromed Basel, Switzerland and fetal calf
 .serum FCS and penicillin were from Seback GmbH
 .Aidenbach, Germany . Oligonucleotide primers were
 .purchased from Microsynth Balgach, Switzerland .
Polyvinylidene difluoride membranes were from Mil-
 .lipore Bedford, MA, USA .
The membrane form of acetylcholinesterase was
purified from bovine erythrocytes as described previ-
w xously 18 . Monoclonal antibody against purified de-
natured GPI-PLD from bovine serum was provided
by Dr. B. Norgaard-Pederson Copenhagen, Den-
. w3 xmark . H myristate-labeled variant surface glyco-
 .protein VSG from Trypanosoma brucei was pre-
w xpared according to Hereld et al. 19 .
2.2. Generation of C-terminal deletions and muta-
tions of GPI-PLD
The plasmid pBJ1682 containing the complete
w xbovine GPI-PLD cDNA 5 was a kind gift from Dr.
 .J. Kochan, Hoffmann-La Roche, Nutley, NJ, USA .
C-terminal deletion mutants were constructed by in-
 .sertion of a premature stop codon TAA using the
polymerase chain reaction with VentTM DNA poly-R
 .merase New England Biolabs, Beverly, MA, USA .
The oligonucleotide primer at the N-terminus for all
reactions was 5X-GAgaattcCGAGCATGTCTGCTT-
TCAG-3X. The C-terminal reverse mismatch primers
were: M814, 5X-CGAgaattcTTAGCCGAGCCTA-
TAGATATGAAGC-3X; M812, 5X-CGAgaattcTTAC-
CTATAGATATGAAGCACCCCAG-3X; M811, 5X-
CGAgaattcTTAATAGATATGAAGCACCCCAGA-
GAG-3X; M810, 5X-CGAgaattcTTAGATATGAAG-
CACCCCAGAGAGTCG-3X; M808, 5X-CGAgaattcT-
TAAAGCACCCCAGAGAG-3X. Substitution of tyro-
sine with alanine was done using the following re-
verse primers: Wt-YrA, 5X-CGAgaattcTTAATCT-
TGGCCGAGCCTAGCGATATG-3X; M811-YrA,
5X-CGAgaattcTTAAGCGATATGAAGCACCCCAG-
AGAG-3X. Mismatches are given in italic characters.
All primers contained an additional EcoRI restriction
 .site indicated in small letters to facilitate cloning.
The wild-type and mutant GPI-PLD cDNAs were
cloned into the EcoRI site of the eukaryotic expres-
 .sion vector pSG5 Stratagene, La Jolla, CA, USA .
w xAll constructs were verified by DNA sequencing 20
using Sequenase version 2.0 sequencing kit USB,
.Cleveland, OH, USA .
2.3. Cell cultures
COS-1 cells were a generous gift from Dr. E.E.
 .Sterchi Bern, Switzerland . COS-1 cells were grown
as monolayers in DMEM supplemented with 10%
 .vrv FCS, 200 Urml penicillin, 1 grl glucose and
2.2 grl NaHCO . Confluent cells were trypsinized,3
diluted 1:10 in DMEM-10% FCS and seeded onto
new cell culture dishes. The medium was changed
every 2–3 days.
2.4. Transient expression of GPI-PLD forms in COS-1
cells
 5.COS-1 cells 4=10 were seeded onto 6 cm
culture dishes 24 h before transfection with DEAE-
w xdextran according to Cullen 21 . The transfection
cocktail containing 0.5 mg GPI-PLD construct in 950
ml PBS 30 mM phosphate, pH 7.4, 120 mM NaCl, 2
.grl glucose and 50 ml DEAE-dextran stock solution
 .10 mgrml in PBS was added to previously washed
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COS-1 cells. The cells were incubated for 30 min at
 .378C. Tissue culture medium 4 ml supplemented
with 100 mM chloroquine was added and the cells
were incubated at 378C for 2.5 h. After a shock with
 .10% vrv DMSO in DMEM for 2.5 min, the cells
were grown for 48–72 h in 5 ml DMEM containing
 .  .10% vrv GPI-PLD-inactivated FCS see below .
2.5. Inacti˝ation of GPI-PLD in FCS
In order to inactivate GPI-hydrolyzing activity pre-
sent in serum, FCS was incubated at pH 11 for 1 h at
378C. Subsequently, the pH was adjusted to pH 7.4
using concentrated hydrochloric acid. After this treat-
ment GPI-hydrolyzing activity was no longer de-
 .tectable i.e. -0.1% of control untreated FCS .
2.6. Assay for GPI-PLD acti˝ity
GPI-PLD activity in cell culture supernatants and
cell pellets was assayed using purified GPI-anchored
acetylcholinesterase from bovine erythrocytes as sub-
strate. Conversion of the amphiphilic GPI-anchored
form of acetylcholinesterase to the soluble enzyme
serves as a measure for anchor-degrading activity
w x22 . The assay was done essentially as described by
w xHeller et al. 16 . GPI-PLD activity measurements in
culture supernatants were done for 4 h in the pres-
 .ence of 0.018% wrv Triton X-100 and in sonicated
 .cell pellets for 2 h in the presence of 0.05% wrv
Triton X-100. GPI-PLD activity was expressed as
arbitrary units or as one unit equaling one picomol
soluble acetylcholinesterase produced per min. In
some experiments GPI-PLD activity was assayed us-
w3 xing H myristate-labeled VSG from T. brucei as
substrate exactly as described by Butikofer and Brod-¨
w x  .beck 23 . Hydrolysis of phosphatidylinositol PI
w xwas measured as described before 23 .
2.7. N-Glycosidase F treatment
N-Glycosidase F treatment was carried out essen-
tially according to the supplier’s instructions Boeh-
.ringer, Mannheim, Germany . Cell pellets of COS-1
cells transfected with the wild-type GPI-PLD con-
struct were sonicated in 100 ml incubation buffer
200 mM sodium phosphate, pH 7.0, 25 mM EDTA,
 . .1% vrv mercaptoethanol . Purified bovine serum
 .GPI-PLD 40 U was dried under vacuum and redis-
solved in 100 ml incubation buffer. Sodium dodecyl
 .sulfate SDS was added to the samples to a final
concentration of 0.1%. After heat denaturation at
958C for 5–15 min, n-octylglycoside was added to a
final concentration of 1% followed by addition of 5
U and 1 U N-glycosidase F to the cell pellet and
bovine GPI-PLD samples, respectively. Incubation
was performed at 378C for 18 h. Control samples
were incubated without N-glycosidase F. Western
blot analysis of the samples was done as described
below.
2.8. Protein assay
Protein concentration was determined using the
BCA reagent kit Pierce Chemicals, Rockford, IL,
.USA . The protein concentration of the cell pellet
was used as a measure for the number of cells.
2.9. Western blot analysis
Sonicated cell pellets of transfected COS-1 cells
were separated by SDS-polyacrylamide gel elec-
 .trophoresis SDSrPAGE using 5–15% gradient gels
 . w xin the presence of 5% vrv 2-mercaptoethanol 24 .
Electroblotting onto polyvinylidene difluoride mem-
w xbranes was performed according to Matsudeira 25 .
Immunostaining of proteins was done as described
w xpreviously 16 using a monoclonal antibody against
denatured GPI-PLD.
3. Results
3.1. Transfection efficiencies
The following steps were taken to minimize possi-
ble differences in transfection efficiencies. First, all
cDNAs were inserted into the same expression vec-
tor; the mutant cDNAs contained only minor dele-
tions or nucleotide substitutions and are not expected
to display inherent differences in transfection rates or
protein expression levels. Second, all plasmids used
in the transfection experiments were purified in an
identical fashion. Third, in all transfection experi-
ments described below the same number of COS-1
cells and the same amount of plasmid was used.
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Fourth, wild-type and mutant cDNAs were trans-
fected simultaneously in each experiment. Fifth, all
transfections were repeated at least four times show-
ing essentially identical results.
3.2. 3.2. GPI hydrolysis by C-terminally truncated
forms of GPI-PLD
The C-terminal amino acid sequences of the wild-
type and mutant forms of GPI-PLD are shown in Fig.
1. All mutations were verified on the cDNA level and
the mutant constructs were expressed in COS-1 cells.
Expression of the different forms of GPI-PLD was
analyzed using SDSrPAGE followed by Western
blotting. All COS-1 cells transfected with the differ-
ent GPI-PLD constructs expressed similar amounts of
 .GPI-PLD Fig. 2A, lanes a–i while mock transfected
 .cells produced no GPI-PLD Fig. 2A, lane k . The
apparent molecular masses of the GPI-PLD con-
structs expressed in COS-1 cells approx. 100 kDa;
.Fig. 2A, lanes a–i were slightly lower than that of
purified GPI-PLD from bovine serum 115 kDa; Fig.
.2A, lane l . This difference is due to altered glyco-
sylation of GPI-PLD in COS-1 cells as compared to
Fig. 1. Construction of C-terminal GPI-PLD mutants. The C-
terminal amino acid sequence of GPI-PLD from position 804 to
816 is shown. Five C-terminal deletion mutants were constructed
by insertion of a premature stop codon: M814, M812, M811,
M810 and M808 deletion of two, four, five, six and eight amino
.acids, respectively . In the M808ext. construct, the M808 mutant
was elongated by 10 random amino acids. In the Wt-YrA and
M811-YrA constructs tyrosine at position 811 of the GPI-PLD
was replaced with alanine by nucleotide substitutions.
Fig. 2. Western blot analysis of GPI-PLD mutants. Proteins were
separated by SDSrPAGE and blotted onto polyvinylidene difluo-
ride membranes. Immunostaining was done with monoclonal
 .antibody against denatured GPI-PLD. A Identical amounts of
protein from sonicated cell pellets of transfected COS-1 cells
 .  .  .  .were loaded in each lane. a wild-type; b M814; c M812; d
 .  .  .  .  .M811; e M810; f M808; g M808ext.; h Wt-YrA; i
 .  .M811-YrA; k mock transfected cells; l purified serum GPI-
PLD. The gel was calibrated with the prestained molecular mass
 . standards phosphorylase B 101 kDa , bovine serum albumin 83
.  .  .kDa , ovalbumin 50.6 kDa , carbonic anhydrase 35.5 kDa ,
 .  .soybean trypsin inhibitor 29.1 kDa and lysozyme 20.9 kDa .
 .B Purified serum GPI-PLD and wild-type GPI-PLD expressed
in COS-1 cells were treated with N-glycosidase F as described in
 .  .Section 2. a untreated serum GPI-PLD; b deglycosylated
 .serum GPI-PLD; c deglycosylated wild-type GPI-PLD ex-
 .pressed in COS-1 cells; d untreated wild-type GPI-PLD ex-
pressed in COS-1 cells. The gel was calibrated with the molecu-
 . lar mass b-galactosidase 116.0 kDa , phosphorylase B 97.4
.  .kDa and bovine serum albumin 66.0 kDa .
the bovine serum enzyme. Actually, recombinant and
serum GPI-PLD have the same apparent molecular
masses of 90 kDa after treatment with N-glycosidase
 .F Fig. 2B .
Culture supernatants and cell pellets were collected
48 h after transfection for the determination of GPI-
PLD activities using GPI-anchored acetylcholineste-
rase as substrate. Total enzyme activities were ex-
pressed relative to the protein contents of the corre-
 .sponding cell pellets as a measure of cell number .
As shown in Fig. 3, the deletion mutants M814,
M812 and M811 deletions of two, four and five
( )B. Stadelmann et al.rBiochimica et Biophysica Acta 1355 1997 107–113 111
Fig. 3. Relative GPI-PLD activities of the different constructs.
GPI-PLD activities in the cell pellets and culture supernatants of
the various GPI-PLD mutants were measured as described in
Section 2. Total GPI-PLD activity in COS-1 cells expressing
 y1 y1wild-type GPI-PLD 6.3"1.0 pmol min mg of cell pellet
.protein was taken as 100%. Total GPI-PLD activities in cells
expressing the mutant forms of GPI-PLD were expressed relative
to the wild-type enzyme. The values represent mean values"
standard deviations of triplicate determinations from n indepen-
dent transfections, with the number of transfections given in
parentheses. GPI-PLD activities in mock transfected cells were
 y1 y1subtracted from all values 0.5"0.2 pmol min mg of cell
.pellet protein .
.amino acids, respectively revealed a reduction in
GPI-PLD activity by roughly 70% as compared to the
wild-type form of GPI-PLD. The deletion mutants
M810 and M808 deletions of six and eight amino
. acids, respectively were catalytically inactive Fig.
.3 . Identical results were obtained using GPI-anchored
 .VSG instead of acetylcholinesterase as substrate
 .data not shown . Tryptic digestion of GPI-PLD, a
procedure which results in the generation of an active
w xN-terminal fragment of bovine serum GPI-PLD 16 ,
did not restore enzymatic activity of GPI-PLD dele-
tion mutant M810, whereas wild-type GPI-PLD re-
 .tained its activity data not shown .
In order to study a possible contribution of the
length of the C-terminus to the enzymatic activity,
the C-terminus of the inactive mutant M808 was
extended by a sequence of 10 random amino acids
 .resulting in the mutant M808ext. Fig. 1 . We found
that COS-1 cells transfected with this construct
 .showed no GPI-PLD activity Fig. 3 , indicating that
one or several specific amino acids at the C-terminus
rather than the total length of the protein are essential
for enzymatic activity.
The relative distribution of GPI-PLD between cell
pellets and culture supernatants was the same in
wild-type and mutant forms of GPI-PLD with 10–
20% of activity in the pellet and 80–90% in the
 .supernatant data not shown . Possible PI hydrolysis
by the different GPI-PLD constructs was studied
using mixed micelles of PIrTriton X-100 as sub-
strates at a PI concentration of 0.05 mM and deter-
gent concentrations of 0.01% and 0.05%. Under none
of these conditions PI hydrolysis was observed, even
when using 10-times more GPI-PLD in combination
with 4-times longer incubation periods.
3.3. Contribution of the tyrosine residue at position
811 to GPI-PLD enzymatic acti˝ity
Based on our findings that GPI-PLD activity was
completely lost after deletion of the tyrosine residue
at position 811, i.e. by going from deletion mutant
M811 to mutant M810, we decided to further analyze
the contribution of this residue to GPI-PLD enzy-
matic activity. We substituted tyrosine 811 in the
wild-type as well as the M811 construct with alanine,
resulting in the mutants Wt-YrA and M811-YrA,
 .respectively Fig. 1 . Our results showed that in both
constructs GPI-PLD activity was decreased by 90–
 .95% as compared to the wild-type enzyme Fig. 3 .
Both mutants expressed similar levels of GPI-PLD
 .protein as the wild-type form Fig. 2A, lanes h–i .
4. Discussion
GPI-PLD is a 115 kDa secretory protein found in
high amounts in mammalian body fluids. Its cDNA
w xhas been isolated and sequenced 5 . Based on tryptic
cleavage experiments the active site of GPI-PLD was
located to a N-terminal fragment of approximately
w x38.6 kDa 16,17 . No function has been reported for
the C-terminus of GPI-PLD. Hints for a possible
involvement of the C-terminus in GPI-PLD enzy-
matic activity came from recent experiments in our
laboratory. First, we found that expression of a N-
terminal domain of 314 amino acids of GPI-PLD in
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COS-1 cells resulted in a total loss of enzymatic
activity. Second, deletion of only 10 amino acids at
the C-terminus of GPI-PLD resulted in a complete
inactivation of the mutant enzyme when expressed in
COS-1 cells Kung, M. and Stadelmann, B., unpub-¨
.lished data . We therefore addressed the question
whether the C-terminal amino acids of GPI-PLD play
a role in maintaining catalytic activity and con-
structed a series of C-terminal deletion mutants and
substitutions. All GPI-PLD constructs were found to
be expressed at similar levels in COS-1 cells. Surpris-
ingly however, deletions of only two to five amino
acids in mutants M814, M812 and M811 reduced
GPI-PLD activity by 70% as compared to the wild-
 .type form Fig. 3 . Furthermore, deletions of six or
eight amino acids in mutants M810 and M808 re-
sulted in a total loss of activity. Extending mutant
M808 by 10 random amino acids did not restore
enzymatic activity, indicating that specific amino
acids rather than the length of the C-terminus are
involved in maintaining GPI-PLD catalytic activity.
The complete lack of catalytic activity in GPI-PLD
 .mutant M810 deletion of six amino acids as com-
 .pared to mutant M811 deletion of five amino acids
together with the drastically reduced enzymatic activ-
ity of the Wt-YrA mutant 10% of wild-type activ-
.ity strongly suggest that the tyrosine residue at posi-
tion 811 plays an important role in maintaining GPI-
PLD catalytic activity.
The complete loss of GPI-PLD activity by deletion
of six to eight C-terminal amino acids from a total of
816 amino acids was surprising. However, a similar
observation has recently been reported for lipoprotein
w xlipase 26 . It was reported that C-terminal deletions
of 6 and 11 amino acids from a total of 448 residues
of lipoprotein lipase reduced the catalytic activity by
20% and 40%, respectively, while the deletion of 16
amino residues resulted in a complete loss of activity.
The reduction in lipoprotein lipase activity of the
deletion mutants was shown to result from a de-
creased stability of the truncated enzymes. In our
case, increased protein instability of the GPI-PLD
mutants can be largely ruled out since the steady-state
levels of the mutant proteins are identical in all
 .transfected cells Fig. 2A . A possible explanation for
the loss of activity in the GPI-PLD mutants may
include misfolding of the protein as a result of the
C-terminal deletions and substitutions. Based on our
present results demonstrating that C-terminal dele-
tions and substitutions resulted in a loss of catalytic
activity, and earlier observations showing that GPI-
PLD activity was associated with the N-terminal
w xdomain of the enzyme 16 , we hypothesize that the
active site of GPI-PLD is located in the N-terminal
portion of the enzyme, whereas the C-terminal part of
the protein is involved in maintaining the structure of
GPI-PLD.
Acknowledgements
We are grateful to M. Boschung for excellent
technical assistance. We also thank S. Jungi for
preparation of the photographs, Dr. J. Kochan for
providing pBJ1682 plasmid and Dr. B. Norgaard-
Pedersen for supply of the monoclonal anti-GPI-PLD
antibody. This work was supported by the Swiss
National Science Foundation Grant No. 31-39209.93.
References
w x1 Davitz, M.A., Hereld, D., Shak, S., Krakow, J., Englund,
 .P.T. and Nussenzweig, V. 1987 Science 238, 81–84.
w x  .2 Davitz, M.A., Hom, J. and Schenkman, S. 1989 J.
Biol.Chem. 264, 13760–13764.
w x3 Huang, K.-S., Li, S., Fung, W.-J.C., Hulmes, J.D., Reik, L.,
 .Pan, Y.-C.E. and Low, M.G. 1990 J. Biol. Chem. 265,
17738–17745.
w x  .4 Hoener, M.C. and Brodbeck, U. 1992 Eur. J. Biochem.
206, 747–757.
w x5 Scallon, B.J., Fung, W.-J.C., Tsang, T.C., Li, S., Kado-Fong,
 .H., Huang, K.-S. and Kochan, J.P. 1991 Science 252,
446–448.
w x  .6 Low, M.G. and Prasad, A.R.S. 1988 Proc. Natl. Acad. Sci.
USA 85, 980–984.
w x  .7 Low, M.G. and Huang, K.-S. 1991 Biochem. J. 279,
483–493.
w x  .8 Hoener, M.C., Stieger, S. and Brodbeck, U. 1990 Eur. J.
Biochem. 190, 593–601.
w x9 Metz, C.N., Zhang, Y., Guo, Y., Tsang, R.C., Kochan, J.P.,
 .Altszuler, N. and Davitz, M.A. 1991 J. Biol. Chem. 266,
17733–17736.
w x  .10 Sesko, A.M. and Low, M.G. 1991 FASEB J. 5, 839
 .abstract .
w x  .11 Stadelmann, B., Zurbriggen, A. and Bordbeck, U. 1993
Cell Tissue Res. 274, 547–522.
w x  .12 Xie, M. and Low, M.G. 1994 Biochem. J. 297, 547–554.
w x  .13 Bernasconi, E., Fasel, N. and Wittek, R. 1996 J. Cell Sci.
109, 1195–1201.
( )B. Stadelmann et al.rBiochimica et Biophysica Acta 1355 1997 107–113 113
w x14 Metz, C.N., Brunner, G., Choi-Muira, N.H., Nguyen, H.,
Gabrilove, J., Caras, I.W., Altszuler, N., Rifkin, D.B., Wil-
 .son, E.L. and Davitz, M.A. 1994 EMBO J. 13, 1741–1751.
w x  .15 Hoener, M.C., Liao, J. and Brodbeck, U. 1994 in: Biologi-
cal membranes: structure, biogenesis and dynamics Op den
.Kamp, J.A.F., ed. vol. H82, pp. 71–78, NATO ASI Series,
Springer Verlag, Berlin Heidelberg.
w x  .16 Heller, M., Butikofer, P. and Brodbeck, U. 1994 Eur. J.¨
Biochem. 224, 823–833.
w x17 Li, J.-Y., Hollfelder, K., Huang, K.-S. and Low, M.G.
 .1994 J. Biol. Chem. 269, 28963–28971.
w x  .18 Brodbeck, U., Gentinetta, R. and Ott, P. 1981 in: Mem-
 .brane proteins Azzi, A., Brodbeck, U. and Zahler, P., eds. ,
pp. 85–96, Springer Verlag, Berlin.
w x19 Hereld, D., Krakow, J.L., Bangs, J.D., Hart, G.W. and
 .Englund, P.T. 1988 in: Post-translational modification of
 .proteins by lipids Brodbeck, U. and Bordier, C., eds. , pp.
9–15, Springer Verlag, Berlin.
w x  .20 Sanger, F., Niklen, S. and Coulson, A.R. 1977 Proc. Natl.
Acad. Sci. USA 74, 5463-5467.
w x  .21 Cullen, B.R. 1987 Methods Enzymol. 152, 684–704.
w x  .22 Stieger, S. and Brodbeck, U. 1988 in: Post-translational
modification of proteins by lipids Brodbeck, U. and Bor-
.dier, C. eds. , pp. 34–39, Springer Verlag, Berlin.
w x  .23 Butikofer, P. and Brodbeck, U. 1993 J. Biol. Chem. 268,¨
17794–17802.
w x  .24 Laemmli, U.K. 1970 Nature 227, 680–685.
w x  .25 Matsudeira, P. 1987 J. Biol. Chem. 262, 10035–10038.
w x26 Bruin, T., Groot, N.B., Jansen, J. and Kastelein, J.J.P.
 .1994 Eur. J. Biochem. 221, 1019–1025.
